CORONA Remedies Limited Announces Audited Financial Results for Q4FY26
CORONA Remedies Limited announced its audited standalone and consolidated financial results for the fourth quarter and year ended March 31, 2026. The Board of Directors approved these results on May 11, 2026. The company published the results in the Financial Express newspaper and made them available on its website.
This is a standard financial results disclosure, which is expected from publicly listed companies and typically has a minimal immediate impact on the stock unless specific, significant deviations from expectations are noted.
The announcement is a routine disclosure of financial results and does not contain any specific positive or negative performance indicators or forward-looking statements.
CORONA Remedies Limited (formerly known as CORONA Remedies Private Limited) has announced its Audited Financial Results for the fourth quarter and the year ended March 31, 2026. The results, which include both standalone and consolidated figures, were considered and approved by the Board of Directors at a meeting held on May 11, 2026.
As per Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company has published an advertisement of these results in the Financial Express newspaper (English and Gujarati). The extract of the newspaper publication is also available on the company's official website, www.coronaremedies.com.
The audited financial results, along with the audit report from M/s. Deloitte Haskins & Sells LLP, Statutory Auditors, are accessible on the company's website and the websites of the BSE Limited and the National Stock Exchange of India Limited.
What to do with a filing like this
CORONA Remedies Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by CORONA Remedies Limited. Read the original for the full detail.